Essentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams

Depression as a leading cardiac risk factor

The American Heart Association recently designated depression as the fourth major risk factor for coronary artery disease, alongside hypertension, high cholesterol, and diabetes, recognizing it as the most disabling condition worldwide.

Physical brain-heart circuitry revealed

TMS targeting the dorsolateral prefrontal cortex activates a measurable pathway through the anterior cingulate, amygdala, and nucleus tractus solitarius into the vagus nerve, allowing clinicians to decelerate heart rate as a direct probe of mood regulation.

The chemical imbalance myth is obsolete

SSRIs do not work immediately and likely exert antidepressant effects through brain plasticity rather than correcting a serotonin deficit, as the chemical imbalance theory has been scientifically disproven.

From permanent deficit to correctable wiring

Psychiatry is evolving from psychotherapy (1.0) and pharmacology (2.0) to a circuit-based model (3.0) that treats depression as reversible electrophysiological dysfunction, like an arrhythmia, rather than a fixed chemical or character flaw.

Five-day TMS induction of remission

Accelerated TMS protocols can restore prefrontal governance over the subgenual cingulate within five days, frequently enabling patients to suddenly comprehend therapy concepts and experience spontaneous mindful presence previously inaccessible to them.

Psychedelics target identical circuits

Psilocybin, ketamine, and MDMA act on the same subgenual default mode network connections as TMS, with MDMA producing clinically significant PTSD relief in approximately two-thirds of patients after just one to two sessions.

Neuroplasticity enables memory reconsolidation

Psychedelics create highly plastic brain states that allow maladaptive evolutionary responses—such as hypervigilance adaptive in combat but destructive at home—to be reconsolidated and resolved without the drug remaining in the system.